Clinical Efficacy and Residue Depletion of 10% Enrofloxacin Enteric-Coated Granules in Pigs

Zhixin Lei, Qianying Liu, Bing Yang, Jincheng Xiong, Kun Li, Saeed Ahmed, Liping Hong, Pin Chen, Qigai He, Jiyue CaoFrontiers in Pharmacology 2017 · DOI

Abstract

This study evaluates a novel 10% enrofloxacin enteric-coated granule (EEG) formulation designed to improve palatability and therapeutic outcomes in swine. Enrofloxacin (ENR) is highly effective against respiratory pathogens like Actinobacillus pleuropneumoniae (APP) and Mycoplasma suis (MS), but its inherent bitterness often leads to drug refusal. Through pharmacokinetic (PK) analysis, residue depletion studies, and clinical trials, researchers determined that a 5 mg/kg dose administered twice daily for five days provides over 90% clinical efficacy. Furthermore, a safe withdrawal period of five days was established to ensure food safety compliance.

Introduction: Overcoming the Bitterness Barrier

Enrofloxacin is a cornerstone antibiotic in veterinary medicine, particularly for treating severe respiratory infections in pigs. However, its bitter taste presents a significant practical challenge: pigs often refuse medicated feed or water, leading to under-dosing and the potential for antibiotic resistance. To address this, researchers developed enteric-coated granules (EEG) that mask the drug's taste and optimize its release in the intestinal tract.

Methodology and Analytical Validation

The study utilized 171 healthy crossbred pigs and clinical strains of APP and MS. Drug concentrations in plasma and various tissues (liver, kidney, muscle, and fat) were measured using high-performance liquid chromatography (HPLC) with a phosphate buffer and acetonitrile mobile phase.

HPLC chromatograms showing the detection of enrofloxacin (ENR) in biological samples across different concentrations.

The analytical method demonstrated high recovery rates (over 84%), meeting the standards of the United States Pharmacopeia (USP). Pharmacokinetic parameters were established following a single 10 mg/kg oral dose, while residue depletion was tracked over five days of repeated 5 mg/kg dosing.

Results and Discussion

In Vitro Antibacterial Activity

Before clinical trials, the EEG formulation was tested against 56 clinical strains of APP. The Minimum Inhibitory Concentration (MIC) distribution showed that the majority of strains were highly sensitive to the drug, with MIC values predominantly falling between 0.03125 and 0.125 µg/ml.

The MIC distribution of EEG against 56 clinical strains of Actinobacillus pleuropneumoniae (APP).

Pharmacokinetics and Residue Depletion

The PK analysis revealed an elimination half-life ($t_{1/2\beta}$) of approximately 15 hours and a peak plasma concentration ($C_{max}$) of 3.38 µg/ml reached at roughly 4 hours ($T_{max}$). This sustained presence in the plasma supports the formulation's efficacy.

Regarding food safety, the residue depletion study found that the drug cleared most quickly from the kidneys and most slowly from the liver. Calculated withdrawal periods for muscle, fat, liver, and kidney were 4.28, 3.81, 4.84, and 3.51 days, respectively.

Clinical Efficacy against APP and MS

In infection models, the 5 mg/kg and 10 mg/kg dosages both achieved over 90% clinical efficacy. These groups showed significant improvements in average daily gain (ADG) and a marked reduction in lung lesion scores compared to untreated controls. The 5 mg/kg dose was identified as the optimal therapeutic level, offering maximum benefit without unnecessary drug use.

Conclusion

The 10% enrofloxacin enteric-coated granules represent a significant advancement in swine medicine. By solving the palatability issue, this formulation ensures reliable dosing and high clinical success against major respiratory pathogens. Based on the residue depletion data, a 5-day withdrawal period is recommended for pigs treated with the optimal 5 mg/kg dose.

Summary updated

Abstract

A new, more palatable formulation of 10% enrofloxacin enteric-coated granules was investigated to evaluate the pharmacokinetic effect in plasma, the residue elimination in tissues and the clinical efficacy against <i>Actinobacillus pleuropneumonia (APP)</i> and <i>Mycoplasam suis (MS)</i> in pigs. In this study, the enrofloxacin concentrations in plasma and tissues were detected using high-performance liquid chromatography with phosphate buffer (pH = 3) and acetonitrile. The pharmacokinetics and elimination of enrofloxacin enteric-coated granules were performed after oral administration at a single dose of 10 mg/kg body weight (bw) and 5 mg/kg twice per day for 5 consecutive days, respectively. The <i>in vivo</i> antibacterial efficacy and clinical effectiveness of enrofloxacin enteric-coated granules against <i>APP</i> and <i>MS</i> were assayed at 2.5, 5, 10 mg/kg, compared with tiamulin (8 mg/kg) based on establishment of <i>APP</i> and <i>MS</i> infection models. 56 <i>APP</i> strains were selected and tested for <i>in vitro</i> antibacterial activity of enrofloxacin enteric-coated granules. The main parameters of elimination half-life (t<sub>1/2β</sub>), T<sub>max</sub>, and area under the curve (AUC) were 14.99 ± 4.19, 3.99 ± 0.10, and 38.93 ± 1.52 μg h/ml, respectively, revealing that the enrofloxacin concentration remained high and with a sustainable distribution in plasma. Moreover, the analysis on the evaluation of enrofloxacin and ciprofloxacin in muscle, fat, liver and kidney showed that the recovery were more than 84% recovery in accordance with the veterinary drug residue guidelines of United States pharmacopeia, and the withdrawal periods were 4.28, 3.81, 4.84, and 3.51 days, respectively, suggesting that the withdrawal period was 5 d after oral administration of 5 mg/kg twice per day. The optimal dosage of enrofloxacin enteric-coated granules against <i>APP</i> and <i>MS</i> was 5 mg/kg, with over 90% efficacy, which was significantly different (<i>p</i> < 0.05) to the 2.5 mg/kg group, but not to the 10 mg/kg group or the positive control group (tiamulin). In conclusion, 10% enrofloxacin enteric-coated granules had significant potential for treating <i>APP</i> and <i>MS</i>, and it provided an alternative enrofloxacin palatability formulation.
BibTeX
@inproceedings{lei2017clinical,
  author = {Zhixin Lei and Qianying Liu and Bing Yang and Jincheng Xiong and Kun Li and Saeed Ahmed and Liping Hong and Pin Chen and Qigai He and Jiyue Cao},
  title = {{Clinical Efficacy and Residue Depletion of 10\% Enrofloxacin Enteric-Coated Granules in Pigs}},
  booktitle = {Frontiers in Pharmacology},
  year = {2017},
  doi = {10.3389/fphar.2017.00294},
}
Figure